Loading…

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

Like this presentation? Why not share!

Practice Based Research - University of Toronto

on

  • 452 views

 

Statistics

Views

Total Views
452
Views on SlideShare
452
Embed Views
0

Actions

Likes
0
Downloads
3
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Practice Based Research - University of Toronto Practice Based Research - University of Toronto Presentation Transcript

  • Practice Based Research at Research Completed in a Hospital Medical / Clinical & Pharmacy Service Related Research Examples of Some Research to demonstrate the breadth of the work and the degree of opportunity & possibility Pharmacy Practice Research Specialty Practice Unique Role and Opportunity
  • Specialty Practice Site in Pharmacy Practice Based Research in Hospital Pharmacy Each Profession must complete research to advance Research improves the knowledge base & credibility and is a method of improving a professions ability to stay current. But who does the research…? Pharmacy leaders are very “knowledgeable” in particular areas Cardiovascular Specialty – CPR/ICU/Care Teams Ambulatory Care Anticoagulation Programs Infectious Diseases Rise to that level of recognition through experience and reading/reviewing current literature (research) related to their area of practice.
  • Most Pharmacy Research is completed by pharmacists who are Pharm D or MSc trained some with residencies and some with post-PharmD fellowships Many work in a specialty environments Cardiovascular Specialty – CPR/ICU/Care Teams Ambulatory Care Anticoagulation Programs Infectious Diseases But … how do you get there? PHARMACY DEPARTMENT with Critical Mass with Common Interest Ability to Complete Research Administrative Support Time
  • Sunnybrook in the 70’s Director: Jim Mann Associate Director: Bill Wilson Coordinators: John Iazzetta Bill Bartle Tom Paton Graduate Studies @ UofT: Dr. Thiessen Kinetics Residency Return to Sunnybrook Bench space grew to an 800 ft 2 Quality Control Laboratory in early 80’s 2 Research Assistants / laboratory technicians Laboratory supplies, etc Annual operating expenditure ~ 100K +
  • Current Resources 1 LC – MS-MS; 2 LC - UV / Fl / EC Freezers, 1 – 80C; 1 -20C 3 computers in the lab plus 3 other computers About 1500 ft 2 in K-Basement Lab Equipment:
  • Research at Sunnybrook Most Work has had an Analytical Requirement Pharmacokinetics IV additive Service Bioequivalence Drug-Drug-Interactions Pharmacodynamic Studies Drug Stability Drug Compatibility Statistics Tyramine Content of Food Herbal Content/Label Claim
  • All studies have been completed through collaboration in fact for most … the idea/the need was generated by someone else a pharmacist … a physician … someone with a practical question These are questions which relate directly to patient care. The questions result in single studies that answer a specific question. The results can be used immediately in a patient Several types of Research Bench Research * Clinical Research * Survey Research Often at a University Funding is often for a program multiple years Generally at a Hospital Funding is for a specific single project which may take several months or several years Can be done anywhere Funding is often for a specific study
  • There are numerous clinical questions for which there is no good data . If you are a pharmacist and you are asked such a question …where do you turn? ? In an HIV patient can we improve response to drug therapy if we make sure that drug concentrations are within a certain range. ? If ciprofloxacin is given to a patient on dialysis, will dialysis increase drug clearance, and if so, what dose is required to replace losses. ? If a patient has an NG tube, can I crush a nifedipine PA tablet Will the patient experience the same clinical response … or must I convert to IV therapy.
  • Simpler questions ? If a patient is taking a herbal medication … will it interfere with other drug therapy? ? If you have 10 different herbal preparations on the shelf – what one is best? ? If the manufacturer of a $300 /IV dose drug says that the drug must be discarded if it is not used immediately, should I discard the medication? ? Can dolasetron and dexamethasone be mixed in the same IV container prior to administration to a patient.
  • Scientific Abstracts Papers John Iazzetta 21 11 Tom Paton 16 14 Bill Bartle 11 12 Sandra Tailor 5 26 Brian Hardy 2 9 Sharon Yamashita 1 5 Graduate Students Lee Dupuis Yana Bacjar Ina Sungaila Debra Kwan Carrie Fung Fran Paradiso-Hardy Robert Lepage All studies have been completed through collaboration in fact for most … the idea/the need was generated by someone else a pharmacist … a physician … someone with a practical question Information current to December 2001
  • Examples of studies completed
    • Compatibility Study
    • Stability Studies
    • Bioequivalence study Iron
    • Tyramine in food
    • Evaluation of content of Herbals
    • Use of handhelds in Clinical Pharmacy
    A pharmacist … a physician asks a question, we try to respond
  • Compatibility Studies. In hospitals, most patients will only have 1 intravenous line running at anyone time. What do you do when a patient has multiple intravenous drugs? Can you give them together ? … or will they ppte in the line? You could given them sequentially … and then flush the line with saline. But this will require excessive nursing time. You could start a second intravenous line …patient? You could test the compatibility. Most studies look at two drugs and present the results in a table Hydromorphone 2 mg/mL 10 mg/mL 40mg/mL Cefazolin 20 mg/mL in D5W C C C Cefazolin 300 mg/mL I recon vial I I I
  • Compatibility of dexamethasone sodium phosphate with hydromorphone hydrochloride or diphenhydramine hydrochloride S COTT E. W ALKER , C ARLO D E A NGELIS , J OHN I AZZETTA , J. G ARY E PPEL Am J Hosp Pharm 48: 2161-6; 1991 When equal volume of dexamethasone (10 mg/mL) and diphenhydramine (50 mg/mL) are mixed a clear but water immiscible liquid is observed. This incompatibility is not visually apparent at lower concentrations. … is this due to compatibility or visual acuity? Equal vol. hydromorphone 50 mg/mL and dexamethasone 2 mg/mL are compatible … but hydromorphone 40 mg/mL and dexamethasone 10 mg/mL are incompatible Are these examples of concentration dependant compatibilities?
  • Develop a method for hydromorphone (H), Dexamethasone (Dx), methylparaben (M), propyl paraben (P), creatinine (C) and degradation products (Dx-1) Then measure concentrations.
  • Dexamethasone & Diphenydramine Equal volumes of D 50 & Dex 10 Equal volumes of D 50 & Dex 4 Region of Incompatibility Region of Compatibility
  • Compatibility Studies Similar graphs have been published for Hydromorphone & Heparin Dexamethasone & Diphenhydramine Dexamethasone & Midazolam Insulin & Labetalol Insulin & Norepinephrine Insulin & dopamine Heparin & Labetolol Heparin & dopamine
  • Stability Studies Manufacturers provide many intravenous drugs as lyophilized powders. … monograph states that following reconstitution that the product should be used immediately (with 24 hours). In most hospital settings, this can contribute to wastage. 24 hours is too little time for a change in dose or a discontinued (unused) IV medication to be re-labeled and given to a second patient. Wastage seems to be related to the Shelf-life. You need time to get the IV dose to a second patient. But … can you move a drug along the line? Can the expiry date be extended?
  • Stability Studies Each dose ~ $30. The top dug on the list in 1986 was cefazolin. With wastage at only 4% monthly expenditures > $16,500. If we used a 24 hour expiry date, wastage could have been ~2640 / month ($31,600 per year). Systematic evaluation of stability and completed the studies which demonstrated expiry dates could be extended to 7 days… or more. Wastage was eventually reduced to less than 3% But … can you move a drug along the line? And why would you want to? Savings in $ 1986 80,000.00 2001 148,000.00
  • Bioavailability Studies Head of Hematology presents two cases of anemia unresponsive to Enteric Coated Ferrous Sulfate tablets Poor clinical response to enteric‑coated iron preparations . R UDINSKAS L, P ATON TW, W ALKER SE, D OTTEN DA, C OWAN DH. Can Med Assoc J. 1989. 141: 565‑566. Problem was that patients responded well & quickly to oral liquid formulations of ferrous sulfate. Was it possible that Enteric Coated Ferrous Sulfate Tablets were not being absorbed? … but they had been on the market since the mid 60’s..!!
  • Bioavailability of oral ferrous sulfate preparations in normal volunteers. W ALKER SE, P ATON TW, C OWAN DH, M ANUEL MA, AND D RANITSARIS G . Can Med Assoc J. 1989. 141: 543‑547. Enteric Coated FeSO 4 tablets had bioavailability of less than 25% … a negative bioavailability was estimated for 1 brand DQTC listing
  • Label Accuracy of Herbal Products A January 2000 S TAR report evaluated 10 brands of each of ginseng, garlic and feverfew, finding between 0% ~85% of label claim in each. “ Its open season on the consumer. When you buy one of these products, it’s an act of faith” Your pharmacy stocks several brands of a particular herbal preparation. What brand should you recommend to patients? Or if you only have limited space … what brand should you stock?
  • Estimating the Concentration of Hypericin(s) in Commercial Products 54 different St John’s wort preparations were purchased 14 US preparations (no tinctures) 4 Walmart (Pittsburgh) 7 Rite Aid Pharmacy in Virginia Beach 3 From 2 other Pharmacies in Virginia Beach 40 Products purchased from Retail Stores in GTA Pharmacies, Health Food Stores, Grocery Stores 12 Tablets 26 Capsules 16 Tinctures Hypericin and pseudohypericin concentrations were determined by chromatography
  • CAPSULE RESULTS Mean Potency: 56.67% Range: 0 % - 108.62% Canadian Potency: 50.26% US Potency: 60.63% p = 0.2611 Naturalife Herb Tech 26 Formulations
  • TABLETS 16 Formulations Mean Potency: 53.57% Range: 5.46% - 81.35% 12 Formulations TINCTURES Mean Concentration: 23.1  g/mL Range: 0 - 110  g/mL 5 mL of Herbal Factors: delivers 550  g Label Rec. 1 mL Equivalent to average Tab or cap The median concentration of a tincture was 6.49  g/ml. In order to provide a dose similar to the median capsule or tablet, you would have to ingest more than 70 mL / dose. Most tinctures come in dropper bottles of 50 mL or less. RESULTS
  • LIMITATIONS Next study evaluated the parthenolide content in Feverfew products, looking at different lots. Most Feverfew products are standardized to 0.2% but some are as high as 0.7% parthenolide 44 different lots of Feverfew products 14 brands of capsules (23 lots), 9 brands tablet/caplet (15 lots) and 6 Tinctures (8 lots) All purchased in Southern Ontario, 1999
    • Analysis consisted of only 1 lot
    • Only naphthodianthrones measured
  • Feverfew Products Percent of Label Claim 18 brands, 30 different lots with label claims Brands: 14 Caps; 9 Tabs; 6 Tinctures No label claim for 5 Caps and all 6 Tinctures Percent of label claim Range of Label Claims Across all brands < 8.4 % to 446% Median ~72% 2/3 are less than 100%
  • Feverfew Products Percent of Label Claim 18 brands, 30 different lots with label claims Brands: 14 Caps; 9 Tabs; 6 Tinctures No label claim for 5 Caps and all 6 Tinctures Percent of label claim Range of Label Claims Within a Brand 418 & 446% 58, 65 & 66% Range of Label Claims within a brand 17%  42%  110% 101%  169%  184%
  • Alternative Product Content Result Summary St Johns Wort. 54 brands, single lots Feverfew 29 brands, 44 lots Content varies from < 8.4% to 446% of label Claim Valerian 19 brands, 30 lots Content varies from 0-108% of Label Claim Glucosamine 53 brands, 77 lots Content varies from 36% to 227% of label Claim Content varies from 39% to 134% of label Claim
  • Tyramine Content of Food Why? In normals, ~450 mg of tyramine increases BP 30 mmHg in 50% of subjects In patient on MAO inhibitors, 8 mg increased blood pressure by 30 mmHg . Question Experimentation by patients is dangerous Can we produce a list that contains only tryramine containing foods? “ cheese effect was reported in ~1963 … hypertensive crisis following ingestion of cheese. Severe headache … nausea …some deaths Problem … case reports of patients on MAOI with headache following ingestion of a food… restriction of the food “ restricted” food list grows to include 200+ items.
  • Tyramine Content of Food Shulman KI, Walker SE, MacKenzie S and Knowles S. Dietary restriction, tyramine and the use of monoamine oxidase inhibitors J clin Psychopharmacol. 1989. 9: 397‑402 . Analysed 111 foods. Identified several foods ( some immature, non-aged cheeses and Chianti Wine ) that did not require restriction Hypertensive Episode Associated with phenelzine and Tap Beer A re-analysis of the Role of Pressor Amines in Beer. Tailor, SAN, Shulman KI, Walker SE, Moss J, Gardner D. J Clin Psycopharmacol 1994; 14: 5-14 79 brands of beer, 98 different samples 38 different brands of tap beers, 30 different canned & bottled beer, 11 dealcoholized beers 4 tap beers containing more than 27 mg/L of tyramine Pizza, “combination foods” … sausage ….
  • Medical based programs ePocrates Rx TM , Clinical Drug Database ePocrates Rx TM , Infectious Disease Guide Patient Tracking Software Pendragon software ePatient 2000 Organization tools Email, Date/Appointments / Addresses & phone Numbers Handhelds in Pharmacy Could you get these devices & programs to help you work more efficiently? Identify patients at risk, gather workload stats, Calculate the cost savings of a clinical recommendation…
  • Other Current Studies Clinical Trials: Evaluation of the Effectiveness of TDM for PI in HIV patients Weekly analysis of PI concentrations in plasma and integration of concentration with HIV virus phenotype to adjust PI dosing. Evaluation of THC to improve appetite in HIV patients Development and analysis of THC, OH & COOH metabolite concentrations in 32 subjects receiving multiple doses of 2%, 4%, & 8% Stability / Compatibility / Analytical Studies : Compatibility & Stability of Pantoprazole Stability of a new formulation of Docetaxel
  • Sources of Funding Pharmaceutical Firms Peer - Review Agencies Ontario Ministry of Heath Ontario HIV Treatment Network Physician Services Incorporated Canadian Institute of Health Research Local Hospital Funding Profit from Pharmaceutical Contract work Collaborators at Sunnybrook John Iazzetta Tom Paton Bill Bartle Sandra Tailor Brian Hardy Sharon Yamashita